| Name | Title | Contact Details |
|---|
bPrescient is a full-service scientific and technology consultancy dedicated to meeting the information management, data science, and analytics needs of the biotech, pharmaceutical, diagnostics, and healthcare industries. With bPrescients industry-leading ecosystem of experts, we offer a unique combination of both depth and breadth of knowledge to provide comprehensive support across: • The entire drug discovery process (from early-stage research to commercialization) • The diagnostics R&D lifecycle • The innovation challenges of the provider / payer domains At bPrescient, we pride ourselves on solving highly complex and difficult challenges. Our clients trust us to provide effective solutions to the problems they face today while anticipating, and helping them avoid, future challenges that catch many organizations unaware. There are three classes of problems we solve for clients: • Strategic & Advisory • Analytical & Scientific • Systems Integration, Design & Build Central to our model is the building of long-term relationships with our clients, which is why we go above and beyond to deliver exceptional results and value to those who need our assistance. Whether you are facing specific challenges today or are thinking about longer-term strategic goals, bPrescient is here to provide the support you need to succeed in the highly competitive biotech, pharmaceutical, diagnostics, and healthcare industries.
HAIMER is a family run, medium sized company located in Igenhausen, Bavaria near Munich, Germany. We design, produce and sell innovative, high precision products for metal cutting as well as for other branches including automotive, aerospace, energy, rail and general machining. In addition to our large offering of tool holders in all popular interfaces and lengths, including our shrinking and balancing machines, as well as our 3-D Sensors and solid carbide cutting tools, our product offering also includes tool presetting machines of HAIMER Microset. Out of approx. 800 employees worldwide, 500 work at our main production facility in Igenhausen together with the most modern of machines and a high level of automation. At our second HAIMER production site in Bielefeld with around 50 employees, HAIMER Microset presetting machines are manufactured. Our experienced, dynamic and highly qualified employees guarantee the well-known and highest quality "made by HAIMER." As an active apprenticeship company with almost 50 apprentices and a high internal acquisition rate, HAIMER is able to secure its future skilled employees and to fulfill its contribution to further educate young adults, as well as securing the future of our German manufacturing location. As the European market leader in the area of tool holding technology, with a daily capacity of max. 4,000 tool holders, keeping the technological edge of our products is very important to us. Because of this, every year we invest between 8 and 10% of our revenue in research and development. Every day we desire to be better and that works perfectly with our corporate philosophy: Quality Wins Imprint Provider/Responsible for the Haimer GmbH website: Haimer GmbH Weiherstr. 21 D-86568 Igenhausen E-mail: haimer@haimer.de Web: www.haimer.com Also: Youtube Xing CEO: Franz Haimer, Claudia Haimer, Andreas Haimer Corporate headquarters: Igenhausen Commercial register: Amtsgericht Augsburg, HRB 8679 VAT ID number: DE 127333346
Exploring Opportunities in the Electric Vehicle Space.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.